Leonard L. Mazur
CIK: 0001463414
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Sep 19, 2025CTOR
CITIUS ONCOLOGY, INC.
Award(A)Direct1.7M shares- - Aug 8, 2025CTXR
Citius Pharmaceuticals, Inc.
Award(A)DirectWarrant to Purchase Common Stock
89.4K shares- - Aug 8, 2025CTXR
Citius Pharmaceuticals, Inc.
Disposition(D)DirectWarrant to Purchase Common Stock
125.5K shares- - Aug 8, 2025CTXR
Citius Pharmaceuticals, Inc.
Award(A)DirectWarrant to Purchase Common Stock
125.5K shares- - Aug 8, 2025CTXR
Citius Pharmaceuticals, Inc.
Disposition(D)DirectWarrant to Purchase Common Stock
89.4K shares- - Dec 12, 2024CTOR
CITIUS ONCOLOGY, INC.
Award(A)DirectStock Option (Right to Buy)
800K shares- - Nov 7, 2024CTXR
Citius Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Purchase Common Stock)
600K shares- - Sep 25, 2024CTXR
Citius Pharmaceuticals, Inc.
Disposition(D)DirectWarrant to Purchase Common Stock
2.2M shares- - Sep 25, 2024CTXR
Citius Pharmaceuticals, Inc.
Award(A)DirectWarrant to Purchase Common Stock
2.2M shares- - Aug 14, 2024CTXR
Citius Pharmaceuticals, Inc.
Disposition(D)DirectWarrant to Purchase Common Stock
3.1M shares- - Aug 14, 2024CTXR
Citius Pharmaceuticals, Inc.
Award(A)DirectWarrant to Purchase Common Stock
3.1M shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 19, 2025 |  CTOR CITIUS ONCOLOGY, INC. | Award(A) | 1,700,000 | - | - | Direct |
| Aug 8, 2025 |  CTXR Citius Pharmaceuticals, Inc. | Award(A) Warrant to Purchase Common Stock | 89,388 | - | - | Direct |
| Aug 8, 2025 | CTXR Citius Pharmaceuticals, Inc. | Disposition(D) Warrant to Purchase Common Stock | 125,490 | - | - | Direct |
| Aug 8, 2025 | CTXR Citius Pharmaceuticals, Inc. | Award(A) Warrant to Purchase Common Stock | 125,490 | - | - | Direct |
| Aug 8, 2025 | CTXR Citius Pharmaceuticals, Inc. | Disposition(D) Warrant to Purchase Common Stock | 89,388 | - | - | Direct |
| Dec 12, 2024 | CTOR CITIUS ONCOLOGY, INC. | Award(A) Stock Option (Right to Buy) | 800,000 | - | - | Direct |
| Nov 7, 2024 | CTXR Citius Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Purchase Common Stock) | 600,000 | - | - | Direct |
| Sep 25, 2024 | CTXR Citius Pharmaceuticals, Inc. | Disposition(D) Warrant to Purchase Common Stock | 2,234,700 | - | - | Direct |
| Sep 25, 2024 | CTXR Citius Pharmaceuticals, Inc. | Award(A) Warrant to Purchase Common Stock | 2,234,700 | - | - | Direct |
| Aug 14, 2024 | CTXR Citius Pharmaceuticals, Inc. | Disposition(D) Warrant to Purchase Common Stock | 3,137,255 | - | - | Direct |
| Aug 14, 2024 | CTXR Citius Pharmaceuticals, Inc. | Award(A) Warrant to Purchase Common Stock | 3,137,255 | - | - | Direct |
1-11 of 11 transactions
About Mazur Leonard L
Mazur Leonard L (SEC CIK 0001463414) files insider reports with the SEC as Chief Executive Officer of CITIUS ONCOLOGY, INC. (CTOR) and Chief Executive Officer of Citius Pharmaceuticals, Inc. (CTXR).
Signal8 holds 7 ownership filings by Mazur Leonard L, all Form 4s, filed between Sep 27, 2024 and Dec 22, 2025. Those filings report 11 transactions, from Aug 14, 2024 to Sep 19, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Mazur Leonard L's filings is in CRANFORD, NJ.
Recent filings by Mazur Leonard L
- Sep 19, 2025: Grant or award of CTOR shares (Form 4, code A).
- Aug 8, 2025: Grant or award of CTXR derivative securities (Form 4, code A).
- Aug 8, 2025: Disposition to issuer transaction of CTXR derivative securities (Form 4, code D).
- Aug 8, 2025: Grant or award of CTXR derivative securities (Form 4, code A).
- Aug 8, 2025: Disposition to issuer transaction of CTXR derivative securities (Form 4, code D).
Other insiders filing for CITIUS ONCOLOGY, INC. (CTOR)
- Peri Jonathan, Director
- Webb Carol, Director
- HOLUBIAK MYRON Z, Secretary
- Czuczman Myron, Chief Medical Officer
- Bartushak Jaime, Chief Financial Officer
- Smith Robert Joseph, Director